Virax Biolabs Group Ltd. Class A's market cap is currently ―. The company's EPS TTM is $-4.22; its P/E ratio is -0.17; Virax Biolabs Group Ltd. Class A is scheduled to report earnings on February 2, 2023, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Mar 23	Sep 22	Mar 22	Sep 21	Mar 21
Income Statement	-
Total Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
EBIT	-	-	-	-	-
EBITDA	-	-	-	-	-
Net Income Common Stockholders	-	-	-	-	-
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 9.35M	$ 4.57M	$ 21.76K	$ 11.68K	$ 17.62K
Total Assets	$ 9.81M	$ 5.30M	$ 48.71K	$ 43.03K	$ 39.62K
Total Debt	$ 146.25K	$ 390.00K	$ 0.00	$ 100.00K	$ 0.00
Net Debt	$ -9.21M	$ -4.18M	$ -21.76K	$ 88.32K	$ -17.62K
Total Liabilities	$ 909.96K	$ 1.14M	$ 1.25M	$ 1.05M	$ 871.43K
Stockholders Equity	$ 9.12M	$ 4.39M	$ -974.58K	$ -798.87K	$ -650.68K
Cash Flow	-
Free Cash Flow	-	-	-	-	-
Operating Cash Flow	-	-	-	-	-
Investing Cash Flow	-	-	-	-	-
Financing Cash Flow	-	-	-	-	-

Currency in USD

Virax Biolabs Group Ltd. Class A Earnings and Revenue History

Income Statement >

Virax Biolabs Group Ltd. Class A Debt to Assets

Balance Sheet >

Virax Biolabs Group Ltd. Class A Cash Flow

Cash Flow >

Virax Biolabs Group Ltd. Class A Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing